AlphaMadera's AlphaVal page computes Anika Therapeutics, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ANIK as undervalued, fairly valued, or overvalued.

What is Anika Therapeutics, Inc.'s fair value?

Fair value for ANIK is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ANIK?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ANIK's most recent reported fundamentals.

ANIK - Anika Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 40% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Strong

Trading 45.8% below fair value

Current Price $15.36

Bear Case $22.68 47.7% upside ($22.68 - $15.36) / $15.36 = 47.7% $1.89 × 12x P/E

Fair Value $28.35 84.6% upside ($28.35 - $15.36) / $15.36 = 84.6% $1.89 × 15x P/E

Bull Case $34.02 121.5% upside ($34.02 - $15.36) / $15.36 = 121.5% $1.89 × 18x P/E

Adjust Assumptions

P/E Multiple

15.0x

Adjusted EPS

1.89$

Key Value Driver

Normalized P/E multiple (15x base case)

Implied Market Multiple 8.1x

Plain-Language Summary

Applying a 15x P/E to adjusted EPS of $1.89, the base-case value is $28.35 per share.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples